8-K: GSK to Acquire RAPT Therapeutics for $2.2 Billion

GSK announced a definitive agreement to acquire RAPT Therapeutics for $58.00 per share in cash, valuing the company at approximately $2.2 billion, to gain its lead asset ozureprubart for food allergies.

Summary

• GSK will acquire RAPT Therapeutics for $58.00 per share in cash through a cash tender offer, followed by a second-step merger.
• The total estimated aggregate equity value of the transaction is $2.2 billion, with GSK's estimated upfront investment, net of cash acquired, at $1.9 billion.
• The acquisition includes ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody, currently in Phase IIb clinical development for prophylactic protection against food allergens.
• Ozureprubart offers the potential for less frequent dosing (every 12 weeks) compared to existing therapies (every 2-4 weeks) and could be an option for approximately 25% of patients currently ineligible for existing treatment.
• The transaction is expected to close in the first quarter of 2026, subject to customary closing conditions, including the tender of a majority of RAPT's outstanding shares and expiration of the HSR Act waiting period.
• RAPT's Board of Directors unanimously determined the transaction is advisable and in the best interest of the company and its stockholders, recommending shareholders accept the offer.

Sentiment

Score: 8

Explanation: The acquisition offers a substantial premium to shareholders and provides RAPT's promising asset, ozureprubart, with the resources of a major pharmaceutical company, addressing a significant unmet medical need with a potentially superior dosing profile. While standard merger risks exist, the strategic fit and financial terms are highly favorable for RAPT and its stakeholders.

Positives

• Shareholders are offered a cash price of $58.00 per share, representing a premium for their investment.
• Ozureprubart, a potentially best-in-class anti-IgE antibody, gains access to GSK's global development and commercialization capabilities, resources, and infrastructure.
• The acquisition addresses a significant unmet medical need in food allergies, a market affecting over 17 million people in the US with substantial health risks and economic burden.
• Ozureprubart's clinical profile suggests less frequent dosing (every 12 weeks) compared to existing therapies (every 2-4 weeks), potentially improving patient compliance and outcomes.
• The therapy could provide a new option for approximately 25% of patients currently ineligible for existing anti-IgE treatments.

Negatives

• RAPT Therapeutics will cease to be an independent publicly traded company following the merger.
• A termination fee of $78.4 million is payable by RAPT to GSK under specified circumstances, such as RAPT accepting a superior proposal or the Board changing its recommendation.
• RAPT is subject to customary 'no-shop' restrictions, limiting its ability to solicit alternative acquisition proposals.
• Certain unvested stock options and restricted stock units (RSUs) granted after March 1, 2025, will convert into cash-based awards with deferred vesting, potentially impacting immediate liquidity for some employees.

Risks

• Uncertainties regarding the timing of the tender offer and the completion of the merger.
• The possibility that RAPT Therapeutics stockholders may not tender a majority of outstanding shares in the offer.
• Potential for competing offers or acquisition proposals to emerge.
• Risk that various closing conditions for the transaction, including required regulatory approvals (e.g., HSR Act), may not be satisfied or may be obtained subject to adverse conditions or limitations.
• The occurrence of any event, change, or other circumstance that could give rise to the termination of the merger agreement.
• Negative effects of the announcement of the proposed transaction on the market price of RAPT Therapeutics common stock or RAPT Therapeutics' operating results.
• Unexpected significant transaction costs associated with the acquisition.
• Risk of litigation and/or regulatory actions related to the proposed transaction.
• Potential adverse reactions or changes to business relationships (e.g., with customers, suppliers, employees, or partners) resulting from the proposed acquisition.
• Risks arising from data protection and cross-border data transfer laws and regulations in jurisdictions where the parties operate, including the People's Republic of China.
• The potential effect of the transaction on RAPT Therapeutics' clinical and preclinical pipeline.

Future Outlook

GSK anticipates that ozureprubart, a long-acting anti-IgE antibody, will provide sustained protection against food allergens with less frequent dosing (every 12 weeks) compared to current therapies. Phase IIb data is expected in 2027, with subsequent Phase III trials planned for adult and pediatric populations. The acquisition is expected to strengthen GSK's Respiratory, Immunology & Inflammation pipeline and address a significant unmet medical need in the food allergy market.

Management Comments

• "The addition of ozureprubart brings another promising new, potential best-in-class treatment to GSKs pipeline. Food allergies cause severe health impacts to patients with existing treatment requiring injections as frequently as every 2 weeks. Ozureprubart offers the opportunity to bring sustained protection to patients with dosing every 12 weeks, and is consistent with our approach to acquire assets that address validated targets and where there is clear unmet medical need." Tony Wood, Chief Scientific Officer, GSK.
• "We are excited to enter into this agreement with GSK, which offers an attractive path forward for our programs, particularly the opportunity we envision for ozureprubart in food allergy. This transaction has the potential to provide access to the global development and commercialisation capabilities, resources and infrastructure that GSK has to offer and ultimately bring added value to our pipeline, patients and stockholders." Brian Wong, President & Chief Executive Officer, RAPT Therapeutics.

Industry Context

The acquisition of RAPT Therapeutics by GSK underscores the pharmaceutical industry's strategic focus on expanding pipelines in high-need therapeutic areas, particularly inflammatory and immunologic diseases. The anti-IgE antibody class is a clinically validated target, and ozureprubart's potential for less frequent dosing could represent a significant advancement, potentially disrupting the existing standard of care and expanding the treatable patient population in the substantial food allergy market. This move aligns with larger biopharma strategies to acquire promising clinical-stage assets to bolster pipelines and leverage established commercial footprints.

Comparison to Industry Standards

• Ozureprubart is a long-acting anti-IgE monoclonal antibody, targeting a clinically validated mechanism for allergic and inflammatory immune responses, similar to existing anti-IgE therapies.
• A key differentiator is its potential for less frequent dosing, with a projected every 12-week regimen, significantly improving upon the current standard of care which requires injections every 2 to 4 weeks. This could lead to improved patient compliance and outcomes.
• Ozureprubart also offers a new treatment option for approximately 25% of patients currently ineligible for existing anti-IgE therapies, expanding the market reach beyond current benchmarks.
• The market for food allergies is substantial, with over 17 million diagnosed individuals in the US and significant healthcare costs (estimated $33 billion in 2024), indicating a strong demand for more effective and convenient treatments.

Management Changes

Corporate Governance

Legal Proceedings

• The filing notes a risk of litigation and/or regulatory actions related to the proposed transaction.
• RAPT is obligated to promptly notify GSK of any securityholder litigation brought against the Company and/or its directors or officers relating to the Transactions, and to allow GSK to review and comment on material filings or responses.

Related Party Transactions

• Certain stockholders of RAPT Therapeutics (collectively, the 'Supporting Stockholders'), holding approximately 0.25% of outstanding shares as of January 16, 2026, entered into Tender and Support Agreements with Parent and Purchaser.
• These agreements obligate the Supporting Stockholders to tender all their shares in the Offer and to vote against any alternative acquisition proposals or actions that would impede the merger.

Stakeholder Impact

• **Shareholders**: Will receive $58.00 per share in cash, providing a clear exit at a premium.
• **Employees**: Unvested stock options and RSUs will convert into cash-based awards, with some deferred vesting, serving as a retention mechanism. Continuing employees will receive comparable base salary, target cash incentives, and aggregate benefits for one year post-merger.
• **Patients/Customers**: Potential for a new, improved therapy (ozureprubart) for food allergies with less frequent dosing and broader eligibility, addressing a significant unmet medical need.
• **GSK**: Strengthens its Respiratory, Immunology & Inflammation pipeline with a promising asset and expands its market presence in allergy treatment.
• **Shanghai Jeyou Pharmaceutical Co., Ltd.**: As RAPT's partner, will receive success-based milestone and royalty payments for ozureprubart from GSK, as per the existing license agreement.

Next Steps

• Purchaser to commence a cash tender offer within 10 business days of January 19, 2026.
• RAPT Therapeutics to file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC.
• GSK, GlaxoSmithKline LLC, and Redrose Acquisition Co. to file a Schedule TO Tender Offer Statement with the SEC.
• Consummation of the tender offer, subject to conditions including majority share tender and HSR Act expiration/termination.
• Second-step merger of Purchaser into RAPT Therapeutics following the tender offer.
• Delisting of RAPT shares from Nasdaq and deregistration under the Exchange Act as promptly as practicable after the merger.
• Phase IIb trial (prestIgE) data for ozureprubart expected in 2027.
• Phase III trials for ozureprubart to focus on adult and pediatric populations.

Key Dates

Recommendation

The acquisition price of $58.00 per share represents a clear and immediate value for RAPT Therapeutics shareholders, likely at a significant premium to its recent trading price. The unanimous approval by RAPT's board and the entry into Tender and Support Agreements by key stockholders indicate strong internal support for the transaction. For investors, this offers a guaranteed cash exit at a premium, making it a strong buy for arbitrage or for existing shareholders to tender their shares. The strategic rationale for GSK, acquiring a potentially best-in-class asset in a high-need area, further solidifies the likelihood of the deal's completion.

Keywords

RAPT Therapeutics, GSK, Acquisition, Merger, Tender Offer, Ozureprubart, Food Allergy, Anti-IgE Antibody, Biopharmaceutical, Clinical Stage, Immunology, Inflammatory Diseases, Immunologic Diseases, Healthcare, Pharmaceuticals